SM-2275

N/A

Report date: 2025/07/30 10:20:11

Base Information

Drug NameSM-2275
Drug Alias NameSM2275SM-2275
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAlbumins modulatorsEpidermal growth factor receptor erbB1 modulatorsProgrammed death-ligand 1 blockers +[4] 
TargetsAlbuminsEpidermal growth factor receptor erbB1Programmed death-ligand 1 +[4] 
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhuhai StarMab BioMed Technology Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhuhai StarMab BioMed Technology Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A